<DOC>
	<DOCNO>NCT01387178</DOCNO>
	<brief_summary>Chronic obstructive pulmonary disease ( COPD ) characterize chronic airflow limitation cause inflammation-mediated damage lung tissue . Although damage lung tissue COPD appear irreversible , evidence suggest course COPD alter measure smoke cessation , pulmonary rehabilitation , use pharmacotherapy bronchodilation . A primary goal maintenance pharmacotherapy reduce incidence acute exacerbation associate hospitalization emergency department ( ED ) visit . Bronchodilation COPD maintenance therapy accomplish long-acting anticholinergic tiotropium ( TIO ) , long act beta-agonists ( e.g . formoterol , salmeterol ) , methylxanthines ( e.g . theophylline ) , combination therapy long-acting beta-agonist inhale corticosteroid ( e.g . fluticasone propionate/salmeterol [ FSC ] ) . The objective study compare benefit combination long-acting beta-agonist/inhaled corticosteroid therapy long-acting anticholinergic therapy . The study compare risk COPD exacerbation COPD-related healthcare utilization cost commercially-insured patient age 40 old prescribe FSC prescribe TIO . The null hypothesis difference exist cost outcomes COPD patient treat TIO treat FSC . The test hypothesis patient treat either TIO FSC incur low cost use few healthcare resource management COPD . The source data study Ingenix Impact database ( formerly Integrated Healthcare Information Services [ IHCIS ] database ) . This administrative claim database include patient-level data enrollment , facility , professional , pharmacy service approximately 50 million patient cover 40 manage care health plan across United States ( US ) . The study design retrospective cohort study .</brief_summary>
	<brief_title>Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 ( FSC ) Tiotropium Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Patient age 40 old Patient record indicate new prescription claim fluticasone propionate/salmeterol ( FSC ) tiotropium bromide ( TIO ) ( first pharmacy claim define index date ) Patient record include least two medical claim primary nonprimary diagnosis COPD ( International Classification Disease9 [ ICD9 ] code 490.xx 492.xx 496.xx ) At least one patient 's ICD9 cod COPD observe 12 month prior first pharmacy claim FSC TIO ( index date ) A pharmacy claim FSC TIO prior index date The patient initiate FSC dose 250µg/50µg The patient initiate FSC TIO time The patient one prescription miss dose information The patient prescription claim study medication one start index date within 60 day index date</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>cost cost analysis</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>healthcare utilization</keyword>
	<keyword>fluticasone propionate/salmeterol</keyword>
	<keyword>tiotropium</keyword>
</DOC>